Amgen Inc (AMGN)vsSandisk Corp (SNDK)
AMGN
Amgen Inc
$347.80
-0.61%
HEALTHCARE · Cap: $187.49B
SNDK
Sandisk Corp
$709.71
-8.08%
TECHNOLOGY · Cap: $104.75B
Smart Verdict
WallStSmart Research — data-driven comparison
Amgen Inc generates 312% more annual revenue ($36.75B vs $8.93B). AMGN leads profitability with a 21.0% profit margin vs -11.7%. AMGN earns a higher WallStSmart Score of 70/100 (B-).
AMGN
Strong Buy70
out of 100
Grade: B-
SNDK
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+47.8%
Fair Value
$665.96
Current Price
$347.80
$318.16 discount
Intrinsic value data unavailable for SNDK.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 106 in profit
Strong operational efficiency at 30.5%
Earnings expanding 112.1% YoY
Large-cap with strong market position
Keeps 21 of every $100 in revenue as profit
Strong operational efficiency at 35.5%
Revenue surging 61.2% year-over-year
Earnings expanding 618.0% YoY
Conservative balance sheet, low leverage
Large-cap with strong market position
Areas to Watch
Expensive relative to growth rate
Trading at 21.6x book value
Trading at 10.3x book value
Grey zone — moderate risk
ROE of -9.4% — below average capital efficiency
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : AMGN
The strongest argument for AMGN centers on Return on Equity, Operating Margin, EPS Growth. Profitability is solid with margins at 21.0% and operating margin at 30.5%.
Bull Case : SNDK
The strongest argument for SNDK centers on Operating Margin, Revenue Growth, EPS Growth. Revenue growth of 61.2% demonstrates continued momentum.
Bear Case : AMGN
The primary concerns for AMGN are PEG Ratio, Price/Book.
Bear Case : SNDK
The primary concerns for SNDK are Price/Book, Altman Z-Score, Return on Equity.
Key Dynamics to Monitor
AMGN profiles as a mature stock while SNDK is a hypergrowth play — different risk/reward profiles.
SNDK is growing revenue faster at 61.2% — sustainability is the question.
SNDK generates stronger free cash flow (980M), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AMGN scores higher overall (70/100 vs 49/100), backed by strong 21.0% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Amgen Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Focused on molecular biology and biochemistry, its goal is to provide a healthcare business based on recombinant DNA technology.
Visit Website →Sandisk Corp
TECHNOLOGY · COMPUTER HARDWARE · USA
Sandisk Corporation (Ticker: SNDK) is a U.S.-based technology company that develops, manufactures, and sells data storage products and solutions built on NAND flash memory technology, including solid-state drives (SSDs), embedded storage, memory cards, and USB flash drives for consumer, enterprise, and cloud computing markets.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?